Fusion Antibodies PLC
LSE:FAB
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
18.2m GBP |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
203.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.1B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
78.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.3B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.9B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.7B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32.1B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.7B USD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Fusion Antibodies PLC is -91.9%, which is above its 3-year median of -122.4%.
Over the last 3 years, Fusion Antibodies PLC’s Net Margin has decreased from -41% to -91.9%. During this period, it reached a low of -196% on Mar 31, 2024 and a high of -41% on Sep 30, 2022.
